EPO and chronic kidney disease: Hypoxia-induced factor (HIF) pathway has been intensively investigated in kidney disease, especially in chronic kidney disease (CKD), as research has shown that HIF-mediated erythropoietin (EPO) synthesis might work as a potential therapeutic strategy for managing CKD-related anemia.